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Introduction: In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin,
vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell
therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not
candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment.
One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent
with antiangiogenic activity.
Case presentation: We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell
lymphoma who had an early relapse after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone. He then had a subsequent early relapse after cisplatin-based salvage consolidated with autologous
stem cell therapy. The efficacy of gemcitabine-cisplatin-rituximab was limited to five months, followed by
systemic and central nervous system progression. Fourth-line treatment with lenalidomide plus rituximab and
involved-field radiotherapy followed by lenalidomide monotherapy greatly improved this patient’s quality of life
and performance status, allowing over two years of progression-free survival to date (excluding a brief relapse
due to treatment interruption).
Conclusion: A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma.
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Although diffuse large B-cell lymphoma (DLBCL) is an
aggressive lymphoma, immunochemotherapy with ritux-
imab, cyclophosphamide, doxorubicin, vincristine, and
prednisone (R-CHOP) - widely regarded as the standard
of care for first-line patients [1,2] - is effective in more
than 50% of cases [3]. Treatment is not as defined for pa-
tients who are refractory or who relapse following stand-
ard first-line therapy. A number of agents are currently in
development for treating relapsed or refractory DLBCL.
Lenalidomide (Revlimid®, Celgene Corporation, Summit,
New Jersey, USA) is an immunomodulatory agent that is
approved for patients with previously treated multiple
myeloma and for patients with myelodysplastic syndrome
who have the 5q cytogenetic abnormality. Lenalidomide
has both direct tumoricidal and immunomodulatory* Correspondence: wojciech.jurczak@lymphoma.pl
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unless otherwise stated.effects. Direct effects include inhibition of vascular
endothelial growth factor-mediated microvessel forma-
tion, indicating antiangiogenic and antimetastatic activ-
ities [4,5], as well as inhibition of nuclear factor kappa
B to bring about cell cycle arrest and tumor cell death
[6]. Immunomodulatory effects of lenalidomide include
inhibition of pro-inflammatory cytokines such as tumor
necrosis factor α, increased anti-inflammatory cytokines
such as interleukin-10, increased cytotoxicity of natural
killer (NK) cells, and inhibition of regulatory T cells
[7-11]. In addition, lenalidomide is a potent enhancer
of NK cell-mediated and monocyte-mediated tumor
cell antibody-dependent cellular cytotoxicity in non-
Hodgkin’s lymphoma cells treated with the anti-CD20
monoclonal antibody rituximab [12].
Numerous studies of lenalidomide in DLBCL as mono-
therapy or in combination with other agents are ongoing in
first-line patients and relapsed or refractory patients, as well
as in the maintenance setting. In first-line patients with
DLBCL, the combination of lenalidomide with rituximabal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in phase 1 and 2 studies [13-18]. In relapsed or refrac-
tory DLBCL, data from phase 2 studies of lenalidomide
monotherapy and combination therapy with rituximab
have been presented [19-24], and overall or objective
response rates range from 28% (DLBCL subset) [20] to
35% [21] in this setting. Based on presumptive cell of
origin, there are two primary DLBCL subtypes with dis-
tinct pathophysiology: germinal center B-cell (GCB)
and activated B-cell (ABC)/non-GCB lymphoma. These
are associated with different prognoses. The ABC/non-
GCB subtype has a significantly poorer prognosis than
the GCB subtype, and this correlation is independent of
the International Prognostic Index (IPI) [25,26]. The
benefit of lenalidomide may differ depending on the
subtype of DLBCL [14,27]. In patients with relapsed or
refractory DLBCL treated with salvage lenalidomide, a
higher overall response rate (ORR) has been observed
in patients with the non-GCB subtype compared with
those with the GCB subtype (ORR 52.9% versus 8.7%;
P=0.006) [27]. The benefit of lenalidomide has also
been reported in newly diagnosed patients with non-
GCB subtype DLBCL treated with R2-CHOP. In this
setting, several small (<70 patients), phase 2 studies
have demonstrated that the addition of lenalidomide
improves progression-free survival and overcomes the
negative prognostic impact of the non-GCB subtype on
patient outcome [14,18]. An ongoing phase 2 random-
ized trial (NCT01856192) is comparing progression-Figure 1 Initial histopathologic examination of the gastric biopsy spe
by the diffuse infiltrate composed of large lymphoma cells. Hematoxylin and
lymphoma cells, objective magnification 40×. (c) PAX5 stain positivity in lymp
diffuse large B-cell lymphoma cells on immunohistochemical staining for MIBfree survival in patients with GCB and non-GCB
DLBCL treated with first-line lenalidomide combined
with R-CHOP versus R-CHOP alone [28]. In vitro studies
indicate that the differential effects of lenalidomide on
non-GCB DLBCL cells are dependent on the expression
of interferon regulatory factor 4 and cereblon, an E3 ubi-
quitin ligase complex co-receptor protein [29].
Prognosis is poor for patients with multiply relapsed
or refractory DLBCL, and current treatment guidelines
suggest either autologous stem cell transplant (ASCT)
or treatment within a clinical trial [1,2], underscoring
the dearth of therapeutic options for this population. In
this report, we present the case of a patient with DLBCL
who received lenalidomide plus rituximab after multiple
relapses on other treatments.
Case presentation
Our 55-year-old Caucasian male patient presented with
a two-month history of gastrointestinal symptoms, in-
cluding severe dyspepsia, vomiting, and ‘black stool.’ At
that time, it was not clear whether our patient’s weight
loss (14kg), high fever (>38.5°C), and drenching night
sweats were general symptoms or whether they were the
result of an undiagnosed gastrointestinal tract disorder.
The first histopathological confirmation of lymphoma
came from a gastric biopsy sample (Figure 1) that con-
firmed CD20-positive DLBCL with a high proliferation
fraction (expressed by Ki67 immunohistochemical stain,
which was positive in 90% of the cells). Furthermore, thecimen. (a) Gastric mucosa occupied (the left two-thirds of the image)
eosin (HE) stain, objective magnification 40×. (b) CD20 stain positivity in
homa cells, objective magnification 40×. (d) High proliferative activity of
-1 (Ki67), objective magnification 40×.
Table 1 Treatment regimen for a heavily pretreated
patient with diffuse large B-cell lymphoma
First-line treatment




Prednisone 40mg/m2 (D1 to D5)
Second-line treatment
R-ESHAP×3 Rituximab 375mg/m2 (D1)
Etoposide 40mg/m2/day (D1 to D4)
Methylprednisolone 500mg/m2/day (D1 to D4)b
Cisplatin 25mg/m2/day (D1 to D4)c
Cytarabine 2000mg/m2 (D5)





Followed by rituximab 375mg/m2,
followed by Y90-labeled ibritumomab





Gemcitabine 1000mg/m2 (D1 to D5)
Cisplatin 80mg/m2 (D1 to D5)
Rituximab 375mg/m2 (D1 to D5)
Prednisone 60mg/m2 (D1 to D5)
Followed by gemcitabine 1,000mg/m2
(every two weeks) and rituximab
375mg/m2 (every four weeks)
Intravenous steroids Dexamethasone 3×8mg
Liposomal cytarabine 50mg (two doses)
Radiotherapy Involved-field RT and prophylactic RT
(26Gy per 10 fractions), then involved-field
RT (8Gy per 1 fraction)
Fourth-line treatment
Lenalidomide 25mg
Rituximab 375mg/m2 (every four weeks)
Palliative RT
Palliative RT
Lenalidomide 10mg/day for 21 days
(every four weeks)
aMaximum 2mg/dose; bmaximum 1,000mg/dose; ccontinuous 24-hour infusion.
D, day; Gy, gray; RT, radiotherapy.
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immunohistochemistry. Our patient was referred from
primary care to a hematologist following analysis of the
gastric biopsy sample. By the time imaging studies were
arranged (one week), generalized lymphadenopathy was
evident, including a cervical lymph node that was nearly
8cm in diameter. Positron emission and computed tom-
ography (PET-CT) imaging demonstrated Ann Arbor
stage IVB with enlarged submandibular, cervical, and me-
diastinal lymph nodes; lung and spleen nodules (172mm);
and gastric infiltration. At the beginning of therapy, our
patient had a high IPI score of 4.
In the first year of therapy (year 1), our patient was
treated with standard R-CHOP chemotherapy (Table 1)
from December of year 1 through May of year 2. A good
clinical response was confirmed on CT imaging per-
formed after cycles four and eight (treatment schema,
Figure 2). Three months after completing first-line ther-
apy, in August of year 2, a complete response (CR) sta-
tus was further confirmed by a PET-CT scan that
revealed cervical lymph nodes (<20mm in the long axis),
with a standard uptake value (SUV) of 2.1, which was
below mediastinal blood pool structure (MBPS) and liver
maximum SUVs (SUVmax) and one 5mm nodule in the
fifth segment of his left lung.
Our patient’s quality of life during first-line treatment
was rather good; symptoms disappeared quickly. For the
most part, he participated in normal daily activities. Treat-
ment was conducted primarily in an outpatient setting.
In December of year 2, CT assessment suggested pos-
sible progression in cervical lymphadenopathy; early re-
lapse was eventually confirmed by histopathology seven
months after completion of the first-line therapy. As a
second line of therapy, our patient received a regimen of
rituximab, etoposide, methylprednisolone, cisplatin, and
cytarabine (R-ESHAP) (Table 1) from March of year 3 to
May of year 3.
A second CR was further consolidated by Z-BEAM-
conditioned (Y90-labeled ibritumomab tiuxetan (Zevalin®,
Spectrum Pharmaceuticals, Henderson, Nevada, USA) com-
bined with the carmustine, etoposide, cytarabine, and
melphalan regimen (BEAM)) ASCT. An initial dose of
rituximab in June of year 3 was followed a week later
by a second rituximab dose plus Y90-labeled ibritumo-
mab tiuxetan and BEAM-conditioned ASCT 11 days
after initiating therapy. Our patient was released from
the hospital in July of year 3, with good hematopoietic
reconstitution and no complications.
At a three-month follow-up visit in October of year 3,
our patient presented with no symptoms or abnormalities
on physical examination. However, a small lesion was de-
tected by PET-CT in his sternum (12mm in diameter,
SUVmax 22.2, MBPS 3.2, liver SUVmax 3.8). A relapse of
his DLBCL with high proliferation fraction was confirmedin material from an urgent partial sternectomy (Figure 3).
Despite this prompt procedure performed by thoracic sur-
geons, the disease progressed in the following months, as
N D
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Figure 2 Treatment schema. ASCT-Z-BEAM, autologous stem cell transplant conditioned by Z-BEAM (Zevalin® and carmustine, etoposide,
cytarabine, and melphalan); CNS, central nervous system; CR, complete response; IFRT, involved-field radiotherapy; PD, progressive disease; PET-CT,
positron emission tomography-computed tomography; PR: partial response; R-CHOP: rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone; R-ESHAP: rituximab plus etoposide, methylprednisolone, cisplatin, and cytarabine; SD: stable disease; Z: Zevalin®.
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imaging.
Our patient’s quality of life during second-line treatment
and ASCT was poor. There were extensive inpatient pe-
riods and side effects from the intensive chemotherapy.Figure 3 Relapse in the sternum. (a) A bone trabecula in the section of th
(DLBCL) infiltrate. Hematoxylin and eosin (HE) stain, objective magnificatio
magnification 40×. (c) CD79a expression varying in intensity in some cell
expression of the Bcl-2 protein in the DLBCL infiltrate, objective magnificFurthermore, his survival concerns caused great stress and
discomfort.
In December of year 3, our patient started third-line,
gemcitabine-based chemotherapy for debulking (Table 1).
He received gemcitabine with cisplatin, rituximab, ande sternal bone infiltrated and destroyed by diffuse large B-cell lymphoma
n 60×. (b) Strong expression of CD20 in the DLBCL cells, objective
s of the neoplastic infiltrate, objective magnification 40×. (d) Strong
ation 40×.
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weeks and rituximab every four weeks.
Beginning in January of year 4, our patient began to
present unspecified, transient symptoms suggestive of
central nervous system (CNS) involvement: headaches
and signs of VII cranial nerve paralysis. Although this
conclusion could not be definitively diagnosed by lumbar
puncture with cerebrospinal fluid (CSF) cytology and re-
peated imaging studies (CT and magnetic resonance im-
aging), intrathecal liposomal cytarabine was given as
CNS prophylaxis. In April of year 4, our patient pre-
sented with diplopia and right-side ptosis. CT scans
demonstrated a left orbit tumor that infiltrated his
frontal sinus. A neurological examination and CSF cy-
tology were otherwise normal. Our patient received
intravenous steroids and liposomal cytarabine, followed
by involved-field radiotherapy (IFRT) of the orbit in
April of year 4 and prophylactic radiotherapy of the
CNS in May of year 4 (Table 1). The diplopia and ptosis
resolved completely, but he developed bone pain in dif-
ferent locations. This was addressed by palliative IFRT
in April of year 4.
During this period of treatment, our patient’s quality
of life remained poor. He was always either home-bound
or hospitalized and was constantly undergoing medical
procedures, including lumbar puncture. He experienced
pain and the loss of some neurological function, and
continued to be in great stress with survival fears.
Our patient remained on the rituximab therapy
(375mg/m2 every four weeks) initiated during third-line
treatment. In May of year 4, he started fourth-line treat-
ment with lenalidomide in addition to rituximab (Table 1).
In June of year 4, he underwent a second round of pallia-
tive radiotherapy for bone lesions in locations correspond-
ing with bone pain (Figure 4).Figure 4 Radiotherapy sites and dates.In September of year 4, PET-CT indicated a partial re-
sponse; only two bone lesions were found (humeral end
of his right clavicle: 17×23mm, SUVmax 7.1; distal and
proximal ends of his right tibia: SUV 4.9; MBPS 3.5, liver
SUVmax 4.2). Our patient remained free of symptoms
until March of year 5, when PET-CT (Figure 5) revealed
lesions of increased SUV in his pelvis, bilateral femur
and tibia, left ankle, and the humeral end of his right
clavicle; SUVmax of these lesions was up to 4.5, MBPS
2.8. An osteolytic lesion in his T12 vertebra was also de-
scribed. Palliative radiotherapy given in April and June
of year 5 was again successful. His pain resolved, and in
a PET-CT assessment in August of year 5, no new skel-
etal lesions were described. The existing lesions were
not metabolically active (lesions in his right femur, SUV-
max 2.1; left femur, 1.8; bilateral tibias, 1.7 (MBPS 1.9,
liver SUVmax 3.2)). The lenalidomide-plus-rituximab
combination was continued until February of year 6,
when treatment was halted for administrative reasons.
Six weeks after stopping lenalidomide-plus-rituximab
therapy, our patient developed palpable lymphadenop-
athy of 5 to 10mm on his neck, prompting initiation of
lenalidomide monotherapy in March of year 6, which
has continued to date. Due to grade 3 neutropenia as
classified by the Common Terminology Criteria for Ad-
verse Events (version 4.0) [30], the lenalidomide dose
was reduced from 25 to 10mg. Since the start of lenali-
domide monotherapy, our patient has not experienced any
progression, with a negative PET-CT in March of year 7,
and has not experienced any bone pain or lesions.
Hematologic adverse events during lenalidomide-based
treatment were manageable and comprised transient
thrombocytopenia (platelets 39,000 to 80,000/μL, no
treatment required), and leuko- and neutropenia (white
blood cells <1000/μL, polymorphonuclear cells <500;
Figure 5 Positron emission tomography-computed tomography
imaging of bone lesions. (a) Acromial extremity of the right
clavicle, March of year 4. (b) Thoracic vertebra T12, March of year 4.
(c) Right ilium, March of year 5. (d) Distal extremity of the femur
bones, March of year 5.
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support). The cytopenia was exacerbated during the
concomitant palliative radiotherapy. Our patient devel-
oped two infections: sinusitis in March of year 5, which
was treated with amoxicillin, and herpes (varicella zos-
ter virus infection limited to the skin of his left cheek,
with severe neuralgia) from July to October of year 5,
which was treated with acyclovir and analgesics.
During treatment with lenalidomide plus rituximab
and then later on lenalidomide monotherapy, our pa-
tient’s quality of life and performance status remained
surprisingly high (World Health Organization grade 0,
Karnofsky score 100%) and much improved compared
with his quality of life and performance status during
previous therapies. Inpatient hospitalization was not re-
quired, all procedures were performed in a day clinic,
and he returned to full-time work and engaged in phys-
ical activities.
Discussion
DLBCL is the most common aggressive non-Hodgkin’s
lymphoma in adults and accounts for 25% to 35% of
newly diagnosed cases [3,31]. Despite the significant ad-
vances with the addition of rituximab to CHOP chemo-
therapy [32,33], 30% to 40% of patients are refractory or
relapse and eventually succumb. This is particularly frus-
trating in younger patients with a high proliferation frac-
tion. Attempts to improve results in this subgroup have
failed despite early intensification of first-line therapy or
consolidation of the first CR with high-dose chemother-
apy supported by ASCT [34]. Prognosis for patients with
an early relapse after R-CHOP therapy in the first line is
particularly poor [35,36], and much worse than previ-
ously reported by the PARMA trial [37].
Lenalidomide has an acceptable toxicity profile and is
easily manageable and effective in heavily pretreated pa-
tients with high-grade lymphoma [38], based on results
from four multicenter phase 2 trials by Wiernik et al. [19],
Witzig et al. [20], Zinzani et al. [21], and Wang et al. [22].
The first two trials explored the efficacy of lenalidomide
monotherapy in relapsing or refractory DLBCL. Lenalido-
mide (25mg for 21 or 28 days) resulted in ORR up to 37%
[22] and median progression-free survival up to four
months [19,22], with median duration of response from
4.6 to 16 months [20,21]. In the third trial, four cycles of
lenalidomide, rituximab, and dexamethasone induction
were followed by lenalidomide maintenance [21]. Al-
though the ORR was similar (35%), it was long-lasting in
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was manageable and well-tolerated, despite the heavily
pretreated population. The most frequent grade 3 or 4
adverse events were hematologic (neutropenia 30%,
thrombocytopenia 14%, asthenia 5%, and anemia 5%)
[21]. These results are confirmed by case reports from
everyday practice. For example, Rubenstein et al. re-
ported remarkable regression of refractory intraocular
DLBCL during monotherapy with lenalidomide [39].
Lenalidomide is not standard treatment for DLBCL at our
institution, although we had previously observed positive
results among our patients participating in clinical trials of
lenalidomide for refractory non-Hodgkin’s lymphoma.
In our patient, we observed an early relapse after first-
line R-CHOP chemotherapy, indicating a dynamic and
aggressive lymphoma with poor prognosis. Although
radioimmunotherapy (ibritumomab tiuxetan) was added
to a BEAM conditioning regimen supported by ASCT, it
did not overcome disease resistance. Considering the
rapid progression of lymphoma at each relapse, it is very
unlikely that local, palliative radiotherapy would have ef-
fectively cured the disease and prevented distant re-
lapses. Treatment with lenalidomide was considered
under compassionate use after failure of all other treat-
ments available at our institution. The lenalidomide-
rituximab regimen was based on Wiernik and Witzig
protocols [19,20]; however, dexamethasone was omitted
to minimize the risk of osteoporosis and compression
fractures in a patient with lymphoma-infiltrated verte-
brae. This regimen changed the lymphoma dynamics,
allowing more effective radiotherapy and possibly pre-
venting its spread to distant sites, and provided the
longest progression-free survival (eight months after the
R-CHOP chemotherapy and three months after Z-BEAM
ASCT versus 12 months on lenalidomide-rituximab until
treatment break followed by >12 months during lenalido-
mide monotherapy). Our patient’s quality of life was excel-
lent and greatly improved compared with previous therapies,
treatment was outpatient-based, and he returned to
work. Furthermore, this positive clinical response and
improved quality of life were maintained despite treat-
ment interruption and continuation as lenalidomide
monotherapy for over 10 months.Conclusions
We demonstrate that lenalidomide can be efficacious in
DLBCL, and we believe that it should be considered in
relapsed or refractory DLBCL, particularly for heavily
pretreated patients.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanyingimages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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